Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia

Table 8 Scenario analyses: cost-effectiveness

	Discontinuation analysis		OAB-5D analysis
	FDC tablet solifenacin 6 mg + TOCAS	Tolterodine + tamsulosin	FDC tablet solifenacin 6 mg + TOCAS	Tolterodine + tamsulosin
Total costs* (£)	860	942	860	959
Difference	–	−82	–	−99
QALYs*	0.839	0.838	0.835	0.831
Difference	–	0.0006	–	0.004
ICER*^‡	–	Dominates (−£133,473)	–	Dominates (−£26,143)

*Per patient at 1 year.
^‡FDC tablet solifenacin 6 mg + TOCAS versus tolterodine + tamsulosin.
FDC, fixed-dose combination; ICER, incremental cost effectiveness ratio; QALY, quality of life adjusted years; TOCAS, oral controlled absorption system (OCAS™) formulation of tamsulosin.

ISSN: 1471-2490